P473 SURVEY ON THE USE OF SGLT2I THERAPY: CLINICAL AND THERAPEUTIC CHARACTERISTICS OF PATIENTS WITH HEART FAILURE IN A GROUP OF CENTERS IN PUGLIA, MOLISE AND ABRUZZO. ANMCO CARDIO RENO METABOLIC AREA

M Benvenuto,C Valenti,E Shehaj,G Panzarella,E Gronda,M Iacoviello

DOI: https://doi.org/10.1093/eurheartjsupp/suad111.535

2023-05-01

European Heart Journal Supplements

Abstract:Abstract Pharmacological treatment of heart failure with reduced ejection fraction has undergone considerable development in recent years. Type 2 sodium–glucose co–transporter inhibitors represent the most recent class of drugs that has been shown to reduce hospital admissions for heart failure and deaths from cardiovascular causes and have immediately entered in the most recent international guidelines for the treatment of HFrEF patients. The objective of this survey, which involved various cardiologists from Puglia, Molise and Abruzzo, was to analyze the clinical characteristics and therapeutic associations of patients in whom SGLT2i therapy was prescribed. Into the REINFORCE project, each of the cardiologists participating in the survey was asked to provide anonymised data of patients who were initiated on SGLT2i therapy. Each cardiologist provided information on the main clinical and therapeutic characteristics of the patients. Data relating to 788 patients on SGLT2i therapy (98.8% dapagliflozin) were analysed. 71% of patients were male, with a mean age of 69.5 years. Approximately 53.5% of the cases had an ischemic heart failure aetiology, 73% had arterial hypertension and 40.6% had type 2 diabetes mellitus. Of these, 83.9% had HFrEF, the 12.3% from HFmrEF and 3.9% from HFpEF. 38.8% of patients had presented an episode of hospitalization for heart failure (in the previous 6 months). At the time of the visit, 23.2% of patients had a serum creatinine value >1.3 mg/dL. 47% of patients were in NYHA Class I–II, while 53% had an advanced class (NYHA III). The analysis of concomitant drug therapies using SGLT2i showed that: 93.4% of the patients were on therapy with a renin angiotensin system inhibitor (40.5% ACEI/ARBs and 52.8% ARNI), 65.9% were on MRA and 91.5% beta blockers. 86.1% of patients were on concomitant diuretic therapy with furosemide. Conclusions Data from the REINFORCE study provide real–world data to help understand the characteristics of heart failure patients prescribed SGLT2i therapy. The data show safety and tolerability of the therapies provided also in the ARNI–SGLT2i association which, associated with efficacy documented in the trials, would suggest to favor this association as soon as possible.

cardiac & cardiovascular systems